NU Skin Enterprises Inc. (NYSE: NUS) reported first-quarter 2026 financial results that fell slightly short of expectations, but management's commentary on brand affiliate confidence and new sales leader growth suggests the company may be nearing a turning point in its business transformation. The company posted revenue of $320.6 million, adjusted net income of $6.8 million, and adjusted earnings per share of $0.14, compared to Stonegate Capital Partners' estimates of $329.7 million, $7.7 million, and $0.15, respectively. Revenue came in near the low end of guidance, while adjusted EPS remained within range as management continued investing behind the Prysm iO platform and emerging markets while maintaining cost discipline.
Key operational metrics showed mixed trends. Core Nu Skin gross margin improved 20 basis points year-over-year to 76.9%, but adjusted operating margin declined to 3.6% from 6.4% in the prior year. More importantly, management reported that brand affiliate confidence improved and new sales leaders grew year-over-year exiting the quarter, suggesting early field stabilization as Prysm iO training and leader engagement scale. This is a critical development for a company that has been navigating a prolonged sales force contraction.
The Prysm iO platform remains the core commercialization catalyst. According to the company, nearly 2 million scans have been conducted across more than 30,000 devices, indicating early adoption. Additionally, subscription volume grew 5% year-over-year, suggesting the platform is beginning to improve customer engagement and recurring revenue quality. This is a positive sign for the company's long-term strategy to shift toward a more subscription-based model.
Despite these encouraging signals, headline key performance indicators remain under pressure. Sales leaders, paid affiliates, and customers declined 13%, 8%, and 14% year-over-year, respectively. However, management's commentary on improving brand affiliate confidence and year-over-year growth in new sales leaders exiting the quarter provides a glimmer of hope that the worst of the contraction may be behind the company.
Looking ahead, NU Skin maintained its full-year 2026 revenue and adjusted EPS guidance of $1.35 billion to $1.50 billion and $0.80 to $1.20, respectively. This guidance implies confidence in a second-half 2026 improvement cadence, supported by broader Prysm iO adoption, India's planned year-end launch, and continued cost discipline. The company's ability to execute on these initiatives will be critical to restoring growth and profitability.
For investors, the key takeaway is that while near-term financial results remain pressured, the underlying trends in brand affiliate confidence and new sales leader growth offer a potential inflection point. The success of Prysm iO in driving customer engagement and recurring revenue will be a key factor to watch in the coming quarters. Stonegate Capital Partners provides equity research coverage on NU Skin Enterprises, and the full announcement is available for further details.
